Successful transplantation depends upon the development of a state of tolerance to the incompatible alloantigens of the graft, especially those of the MHC system. The current state in the clinic is one of short tcrm success, but states of tolerance not requiring the use of powerful and toxic immunosuppressive agents are not easily achievable. The intestine has an elaborate immune system which is incompletely understood. Although the oral route can be used for immunization, there are many experimental examples of tolerance induction, including prevention or treatment of autoimmune disease in animal models . There has been little reported with regard to transplantation. Advances in the molecular biology and structure of the molecules of the MHC, as well as improved definition of the functional varieties of effector and regulatory T cells, now make it possible to perform experiments which should lead to knowledge on how to take advantage of the intestinal immune system's abilities to influence immune responses in a negative direction. Synthetic peptides representing the polymorphic regions of rat class II MHC have been shown after oral feeding to partially tolerize T cells in vitro and in vivo in an antigen specific manner. The study will aim to address the questions of the relationship between immunogenicity and tolerogenicity of MHC peptides, the mode of action with regard to T cell anergy versus suppression, the uniqueness of the proliferative responses of the intestinal epithelial T cells and the peptide presenting capacity of epithelial cells, and optimization of oral feeding to the prolongation of allografts. Rat and mouse murine models will be used, including mice tolerized to Mls immunization and T cell receptor transgenic mice. Mechanisms which involve cytokines with potential downregulatory function (e.g., TGFbeta, IL-4,IL-10) will be pursued.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI033100-02
Application #
3148216
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1992-07-01
Project End
1997-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Womer, Karl L; Magee, Colm C; Najafian, Nader et al. (2008) A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients. Clin Transplant 22:754-9
Salama, Alan D; Najafian, Nader; Clarkson, Michael R et al. (2003) Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 14:1643-51
Kist-van Holthe, Joana E; Gasser, Martin; Womer, Karl et al. (2002) Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney Int 62:627-31
Donato, Jose L; Ko, Jon; Kutok, Jeffery L et al. (2002) Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest 109:51-8
Najafian, Nader; Salama, Alan D; Fedoseyeva, Eugenia V et al. (2002) Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 13:252-9
Frank, M H; Denton, M D; Alexander, S I et al. (2001) Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 166:2451-9
Stadlbauer, T H; Schaub, M; Magee, C C et al. (2000) Intrathymic immunomodulation in sensitized rat recipients of cardiac allografts: requirements for allorecognition pathways. J Heart Lung Transplant 19:566-75
Murphy, B; Magee, C C; Alexander, S I et al. (1999) Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest 103:859-67
Onodera, K; Chandraker, A; Volk, H D et al. (1999) Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation 68:288-93
Lara-Marquez, M L; Deykin, A; Krinzman, S et al. (1998) Analysis of T-cell activation after bronchial allergen challenge in patients with atopic asthma. J Allergy Clin Immunol 101:699-708

Showing the most recent 10 out of 40 publications